Printer Friendly
The Free Library
14,709,470 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Alfacell Corporation to Present at IBC Life Sciences' Antibody Engineering Conference.


Company to Discuss Novel Targeted Therapeutics from its RNase Technology Platform

BLOOMFIELD, N.J. -- Alfacell Corporation (NASDAQ NASDAQ
 in full National Association of Securities Dealers Automated Quotations

U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on
: ACEL ACEL Australian Council for Educational Leaders (Australia)
ACEL Aerospace Crew Equipment Laboratory
ACEL Alternating Current Electro-Luminescent
), a biopharmaceutical company focused on the discovery, development and commercialization of novel ribonuclease Ribonuclease

A group of enzymes, widely distributed in nature, which catalyze hydrolysis of the internucleotide phosphodiester bonds in ribonucleic acid (RNA).
 (RNase) therapeutics for cancer and other life-threatening diseases, today announced that Dr. Susanna Rybak, a member of Alfacell's Scientific Advisory Board, is an invited speaker at IBC IBC International Building Code
IBC Iraq Body Count
IBC Institutional Biosafety Committee
IBC Inflammatory Breast Cancer
IBC International Business Company
IBC Independence Blue Cross
IBC Insurance Bureau of Canada
IBC International Broadcasting Convention
 Life Sciences' 17th Annual Conference on Antibody Engineering and Immunotherapeutics for the 21st Century, to be held December 10-14, 2006 in San Diego San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. , CA.

Dr. Rybak's presentation, entitled "RNase-based Targeted Therapeutics," will feature research conducted at the National Cancer Institute and Alfacell involving the Company's lead investigational drug candidate, ONCONASE([R]) (ranpirnase), and, specifically, the creation of an anti-CD22 antibody-ONCONASE molecule that very effectively kills human non-Hodgkin's lymphoma non-Hodg·kin's lymphoma
n.
Any of various malignant lymphomas characterized by the absence of Reed-Sternberg cells.


Non-Hodgkin's lymphoma 
 cells. Highlights of work from another Alfacell research collaborator, Dr. Juergen Krauss from the University of Duisburg-Essen The University of Duisburg-Essen (German: Universität Duisburg-Essen) is a university institution situated in the German federal state of North Rhine-Westphalia. , will also be presented. Dr. Krauss's work involves the creation of novel immunomodular forms suitable for specifically targeting ONCONASE to tumors. Dr. Krauss and Alfacell are collaborating to build a portfolio of antibody-ONCONASE targeted immunotherapeutics.

For more information about the conference, visit www.ibclifesciences.com/antibodyeng.

Alfacell Corporation

Alfacell Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer and other life-threatening diseases, using its proprietary ribonuclease (RNase) technology platform. For more information, please visit http://www.alfacell.com.

Safe Harbor Safe Harbor

1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated.

2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive.
 

This press release includes statements that may constitute "forward- looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the Company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the Company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the Company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
COPYRIGHT 2006 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 11, 2006
Words:374
Previous Article:Shareholders of First Trust Value Line(R) Dividend Fund Approve Reorganization into Exchange-Traded Fund.
Next Article:FSMLabs Enables Real-Time Carrier Grade Applications on AMD Opteron(TM) Processor-Based ATCA.
Topics:



Related Articles
ALFACELL scientists report on characterization of a natural variant of ONCONASE; Data presented at 4th International Ribonuclease Conference.
Onconase-anti-CD22 Monoclonal Antibody Conjugates Produce Significant Prolongation of Survival in Scid Mice.
Alfacell Receives New U.S. Patent and Broadens Relationship With the National Cancer Institute -NCI-; New Patent Protects Gene Sequences of Company's...
Merger proposed between Informa Group and Taylor & Francis.
HTS Biosystems and Dyax Corporation Enter Collaboration Agreement.
Lines being drawn in building codes battle.
MedImmune Licenses Xencor's XmAb(TM) Technology to Create Antibody Therapeutics against Select Tumor Targets; Fifth XmAb(TM) Deal for Xencor in the...
Xencor Data Published in PNAS Show Engineering the ''Fc'' Region of Antibodies Makes Them More Toxic to Cancer Cells.
Alfacell Selects TS Communications and Feinstein Kean Healthcare for Comprehensive Integrated Communications.
Alfacell Corporation to Present at C.E. Unterberg, Towbin Life Sciences Conference.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles